MannKind (MNKD) Posts Q4 Loss of 66c/Share
Get Alerts MNKD Hot Sheet
Revenue Growth %: +48.9%
Financial Fact:
Net loss: 126.52M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
MannKind (NASDAQ: MNKD) reported Q4 EPS of ($0.66), which may not compare with the analyst estimate of ($0.05).
Sales of Afrezza continued to be lower than expected during the fourth quarter of 2015, culminating in a decision by Sanofi on January 4, 2016 to return the Afrezza rights to MannKind after a notice period, all of which impacted the value and recoverability of long-lived assets in accordance with accounting guidance. As a result, non-cash impairment charges of $206.6 million were recorded for the fourth quarter of 2015, of which $140.4 million related to impairment of fixed assets and $66.2 million related to loss on future purchase commitments, primarily for insulin.
For earnings history and earnings-related data on MannKind (MNKD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PHINIA Inc. (PHIN) Reports Q1 EPS of $1.08, provides guidance
- Hess Midstream Partners LP (HESM) Misses Q1 EPS by 5c, reaffirms guidance
- California Water Service (CWT) Tops Q1 EPS by 111c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!